Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
出版年份 2020 全文链接
标题
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-13
DOI
10.1186/s13045-020-00885-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Optical Control of Small Molecule-Induced Protein Degradation
- (2020) Yuta Naro et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- PHOTACs enable optical control of protein degradation
- (2020) Martin Reynders et al. Science Advances
- Very low intensity ultrasounds as a new strategy to improve selective delivery of nanoparticles-complexes in cancer cells
- (2019) Rossella Loria et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- The BAF complex in development and disease
- (2019) Amelie Alfert et al. Epigenetics & Chromatin
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Emerging roles of and therapeutic strategies targeting BRD4 in cancer
- (2019) Mary E. White et al. CELLULAR IMMUNOLOGY
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- From Inhibition to Degradation: Targeting the Anti-apoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
- (2019) James William Papatzimas et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment
- (2019) Keiko Yamakawa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
- (2019) Ziqian Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
- (2019) Patrick Pfaff et al. ACS Central Science
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
- (2019) Thomas H. Pillow et al. ChemMedChem
- BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation
- (2019) Drishti Rathod et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Light-Induced Protein Degradation with Photocaged PROTACs
- (2019) Gang Xue et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
- (2019) Chengcheng Shi et al. Cell Death & Disease
- Structure-Based Design of a Macrocyclic PROTAC
- (2019) Andrea Testa et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- STAT3, stem cells, cancer stem cells and p63
- (2018) Michaela Galoczova et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation
- (2018) Shihui Wang et al. CHEMICAL RESEARCH IN CHINESE UNIVERSITIES
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
- (2018) Xiaohui Zhang et al. LEUKEMIA
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
- (2018) Taavi Neklesa et al. CANCER RESEARCH
- STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
- (2018) Stephen D'Amico et al. GENES & DEVELOPMENT
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- FLT3 inhibitors in acute myeloid leukemia
- (2018) Mei Wu et al. Journal of Hematology & Oncology
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- In VivoKnockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
- (2017) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
- (2017) Ryan P. Wurz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- FDA-Approved Oligonucleotide Therapies in 2017
- (2017) Cy A. Stein et al. MOLECULAR THERAPY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Delivery technologies for genome editing
- (2017) Hao Yin et al. NATURE REVIEWS DRUG DISCOVERY
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
- (2017) Bao Nguyen et al. Oncotarget
- Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau
- (2017) Na Gao et al. RSC Advances
- Immunomodulatory Effect of Flavonoids of Blueberry (Vaccinium corymbosum L.) Leaves via the NF-κB Signal Pathway in LPS-Stimulated RAW 264.7 Cells
- (2017) Dazhi Shi et al. Journal of Immunology Research
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling
- (2016) Rory T. Coffey et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Cornerstones of CRISPR–Cas in drug discovery and therapy
- (2016) Christof Fellmann et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
- (2016) Honorine Lebraud et al. ACS Central Science
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Oligonucleotide Therapies: The Past and the Present
- (2015) Karin E. Lundin et al. HUMAN GENE THERAPY
- Knocking down disease: a progress report on siRNA therapeutics
- (2015) Anders Wittrup et al. NATURE REVIEWS GENETICS
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
- (2015) Ryan M. Young et al. SEMINARS IN HEMATOLOGY
- Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance
- (2014) M. Buscarlet et al. BLOOD
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Regulation of STAT signaling by acetylation
- (2013) Shougang Zhuang CELLULAR SIGNALLING
- Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation
- (2013) J. Silke et al. Cold Spring Harbor Perspectives in Biology
- Inhibitor Mediated Protein Degradation
- (2012) Marcus J.C. Long et al. CHEMISTRY & BIOLOGY
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
- (2012) Oliver Hantschel et al. Nature Chemical Biology
- Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
- (2011) Taavi K Neklesa et al. Nature Chemical Biology
- Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
- (2011) Ellen Weisberg et al. PLoS One
- Mcl-1; the molecular regulation of protein function
- (2010) Luke W. Thomas et al. FEBS LETTERS
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Protacs for Treatment of Cancer
- (2010) Kathleen M Sakamoto PEDIATRIC RESEARCH
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
- (2009) Abdalla J. Mohamed et al. IMMUNOLOGICAL REVIEWS
- Quality Control Against Misfolded Proteins in the Cytosol: A Network for Cell Survival
- (2009) H. Kubota JOURNAL OF BIOCHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search